SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Posted on by

Milestone Coincides with SK Biopharmaceuticals’ Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide GYEONGGI, Korea, and ROME, March 11, 2024 /PRNewswire/ — SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.